Plus Therapeutics (PSTV) announces continued operational execution and commercial progress in the launch of its wholly owned subsidiary, CNSide Diagnostic’s, Cerebrospinal Fluid Tumor Cell Enumeration laboratory developed test. “Russ and Daniel, alongside other recent hires, will be key drivers in the execution of our ambitious plans to serve the large unmet medical need in central nervous system cancer diagnosis and treatment,” said Marc Hedrick, M.D., Plus Therapeutics President and Chief Executive Officer. “The promotion of these proven leaders will give them greater impact across their organization and help ensure we meet our operational and commercial targets.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PSTV:
- PSTV Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Buy Rating for Plus Therapeutics Driven by Strategic Advancements and Market Expansion for CNSide Test
- Buy Rating for Plus Therapeutics Driven by CNSide Coverage and Promising Pipeline Developments
- Plus Therapeutics announces national coverage agreement with UnitedHealthcare
- Plus Therapeutics announces $1.9M advance payment from CPRIT